drugset / Trial / NCT00872885

Bunionectomy Trial With GRT6005

NCT00872885

Phase 2 Completed 258 enrolled Tris Pharma, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the trial is to determine whether the new centrally acting analgesic is effective in comparison to placebo and an active comparator (morphine).

Timeline

Start
2009-03
Primary completion
2009-08
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cebranopadol Small molecule 200 ug
Subject Cebranopadol Small molecule 600 ug
Comparator Morphine Other / unclassified 60 mg

Indications

No indication recorded.